Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Drugs In Development, 2022'; Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Gamma-aminobutyric acid A receptor, alpha 3 or GABRA3 is a protein encoded by the GABRA3 gene. GABRA3 are ligand-gated chloride channels and are activated by the major inhibitory neurotransmitter in the mammalian brain and has been found to mediate anxiolytic activity, which plays a key role in emotional and behavioral control.

The report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Drugs In Development, 2022' outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System, Dermatology and Genito Urinary System And Sex Hormones which include indications Anxiety Disorders, Epilepsy, Neuropathic Pain (Neuralgia), Depression, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Fibromyalgia (Fibromyalgia Syndrome), Panic Disorders, Primary Hyperoxaluria, Primary Hyperoxaluria Type I, Primary Hyperoxaluria Type II and Pruritus.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)
• The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics and enlists all their major and minor projects
• The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope